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ABSTRACT  
Background: Patient-reported outcomes are integral in benefit-risk assessments of new 
treatment regimens. The PALOMA-2 study provides the largest body of evidence for patient-
reported health-related quality of life (HRQOL) for patients with metastatic breast cancer 
receiving first-line endocrine-based therapy (palbociclib plus letrozole and letrozole alone).  
Patients and Methods: Treatment-naïve postmenopausal women with estrogen receptor–
positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) metastatic breast 
cancer were randomized 2:1 to palbociclib plus letrozole (n=444) or placebo plus letrozole 
(n=222). Patient-reported outcomes were assessed at baseline, day 1 of cycles 2 and 3, and day 
1 of every other cycle from cycle 5 using the Functional Assessment of Cancer Therapy (FACT)–
Breast and Euro-QOL- 5 Dimension (EQ-5D) questionnaires.  
Results: As of 26 February 2016, the median duration of follow-up was 23 months. Baseline 
scores were comparable between the 2 treatment arms. No significant between-arm 
differences were observed in change from baseline in FACT-Breast Total, FACT−General Total, 
or EQ-5D scores. Significantly greater improvement in pain scores was observed in the 
palbociclib plus letrozole arm (–0.256 vs –0.098; P=0.0183). In both arms, deterioration of 
FACT–Breast Total score was significantly delayed in patients without progression vs those with 
progression and patients with partial or complete response versus those without. No significant 
difference was observed in FACT–Breast and EQ-5D index scores in patients with and without 
neutropenia.  
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Conclusions: Overall, women with metastatic breast cancer receiving first-line endocrine 
therapy have a good quality of life. The addition of palbociclib to letrozole maintains health-
related quality of life and improves pain scores in treatment-naïve postmenopausal patients 
with ER+/HER2– metastatic breast cancer compared with letrozole alone. Significantly greater 
delay in deterioration of health-related quality of life was observed in patients without 
progression versus those who progressed and in patients with an objective response versus 
non-responders.  
(ClinicalTrials.gov: NCT01740427) https://clinicaltrials.gov/ct2/show/NCT01740427 
 
Keywords: palbociclib, letrozole, health-related quality of life, metastatic breast cancer, 
ER+/HER2‒ 
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Key Message  
 
In PALOMA-2, adding palbociclib to letrozole maintained health-related quality of life (HRQOL) 
in treatment-naïve postmenopausal patients with estrogen receptor–positive/human 
epidermal growth factor receptor 2–negative metastatic breast cancer. This observation is 
maintained regardless of the occurrence of neutropenia while deterioration of HRQOL is 
delayed in patients without progression.  
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INTRODUCTION 
Endocrine therapy is the primary treatment option for patients with treatment-naïve estrogen 
receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) 
metastatic breast cancer (MBC). However, all patients eventually develop tumor progression or 
have primary tumor resistance to endocrine treatments. Improving response and prolonging 
the duration of response to endocrine-based therapy while maintaining or improving quality of 
life (QOL) is an important treatment goal. The addition of agents targeted to pathways 
contributing to resistance may improve response and delay progression, but it is critical to 
understand both the safety profile and the impact of these therapies on QOL.[1, 2] As such, 
patient-reported outcomes (PROs) are an integral component of benefit-risk assessments in the 
evaluation of new treatment regimens. 
Palbociclib (Ibrance, Pfizer, New York, NY, USA) is an orally bioavailable small-molecule 
inhibitor of cyclin-dependent kinases (CDKs) 4 and 6.[3] The recently reported results from the 
primary endpoint of the phase 3 study (PALOMA-2) demonstrated a significant improvement in 
PFS with palbociclib plus letrozole (median 24.8 vs 14.5 months; hazard ratio [HR]:0.58; 95% 
confidence interval [CI], 0.46–0.72; P<0.001) versus placebo plus letrozole.[4] The main 
objective of the current report describes the impact of palbociclib and letrozole combination 
therapy on patient-reported QOL in PALOMA-2 (NCT01740427). 
PATIENTS AND METHODS 
Study Design and Participants 
Downloaded from https://academic.oup.com/annonc/advance-article-abstract/doi/10.1093/annonc/mdy012/4817337
by guest
on 06 February 2018
6 
PALOMA-2 is an international (17 countries), randomized, double-blind, placebo-controlled, 
parallel-group, phase 3 study in which postmenopausal women with ER+/HER2‒
advanced/metastatic breast cancer who had not received systemic anticancer treatment for 
advanced disease (ie, treatment-naïve) were randomized 2:1 to palbociclib plus letrozole 
(n=444) or placebo plus letrozole (n=222). All randomized patients received study therapy 
(Figure S1); additional methods are published elsewhere.[4] The study was performed in 
compliance with ethical principles outlined in the Declaration of Helsinki; the study protocol 
was approved by local review boards at each investigational center. 
Treatment 
Palbociclib or placebo was administered orally 125 mg daily for 21 days of every 28-day cycle 
followed by 7 days off. Letrozole was administered orally 2.5 mg on a continuous daily dosing 
schedule.  
Patient-Reported Outcomes 
Patient-reported health-related quality of life (HRQOL) outcomes, a secondary objective in the 
PALOMA-2 trial, were assessed using the fully validated Functional Assessment of Cancer 
Therapy-Breast (FACT-B) and EuroQoL (EQ-5D) questionnaires at baseline, day 1 of cycles 2 and 
3 and day 1 of every alternate cycle from cycle 5 until disease progression or end of study 
treatment.[5-7] Patients completed the self-assessment questionnaires at the study site. The 
FACT-B was chosen as it is a well validated questionnaire to assess breast cancer-specific 
HRQOL. The majority of patients in the validation study for this instrument had stage IV breast 
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cancer; hence, the instrument was considered appropriate to assess HRQOL in the PALOMA-2 
study. 
The FACT-B (version 4, 1997) measures multidimensional breast cancer–specific HRQOL 
using a 37-item self-reporting instrument containing the 27-question FACT-General (FACT-G) 
survey and a 10-question breast cancer–additional concerns scale.[5] Patients are asked to 
respond to each question on a Likert scale where 0=not at all, 1=a little bit, 2=somewhat, 
3=quite a bit, and 4=very much. FACT-B produces 5 subscale scores that reflect the patient’s 
QOL: physical well-being (PWB), social/family well-being (SWB), emotional well-being (EWB), 
functional well-being (FWB), and a breast cancer subscale (BCS). The BCS was calculated using 
the first 9 of 10 items in our analyses with the last item assessing pain excluded as 
recommended by the scoring guidelines for FACT-B v4.0. These subscale scores were used to 
derive 3 assessment outcomes—FACT-B total score, FACT-G total score, and FACT-B Trial 
Outcome Index (TOI), which are defined as follows: 
FACT-B total score=PWB+SWB+EWB+FWB+BCS 
FACT-G total score=PWB+SWB+EWB+FWB 
TOI score=PWB+FWB+BCS 
Subscale scores were calculated if over 50% of the component individual items in that 
subscale are non-missing; the total scores were calculated if over 80% of the component items 
are non-missing and all the component subscales have valid scores. 
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A higher score in any FACT-B assessment indicates better QOL. A meaningful change in 
QOL is defined as a change in baseline score equal to or greater than the established minimally 
important differences (MID): FACT-G=5–6 points and FACT-B=7–8 points.[8] The tenth item of 
the BCS (P2) assessing severity of pain in certain parts of the body was analyzed as an individual 
item separate from the BCS. A higher raw score on the pain item indicates higher pain severity. 
The EQ-5D questionnaire[6] is composed of a 5-item health status measure and a visual 
analog scale (VAS) administered separately and used to generate 2 different scores, the EQ-5D 
index and the VAS general health status. The EQ-5D index score is based on answers to a 5-item 
questionnaire evaluating mobility, self-care, usual activities, pain, discomfort, and 
anxiety/depression. Answers received a score ranging from 1 to 3, depending on whether 
patients perceived no problems (=1), some problems (=2), or extreme problems (=3) in that 
aspect of their health. Summary scores were calculated using an algorithm based on societal 
preferences from general population-based valuation studies in the United Kingdom (0=death, 
1.0=perfect health).[6] A higher EQ-5D index score indicated a better QOL. The EQ-5D VAS 
generates a single health status score in which patients are asked to rate their current health on 
a VAS ranging from 100 (best imaginable health state) to 0 (worst imaginable health state). 
Statistical Analyses 
PRO analyses were based on the PRO-evaluable population (ie, patients in the intent-to-treat 
[ITT] population with a baseline and ≥1 post-baseline assessment before the end of study 
treatment). Completion rates were summarized by cycle in the ITT population. The primary 
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prespecified PRO endpoint was HRQOL assessed by the FACT-B total score. Other PRO 
endpoints included FACT-G total score, FACT-G subscale scores, BCS, TOI, EQ-5D index score, 
EQ-VAS general health status score. For each questionnaire (FACT-B and EQ-5D), a completion 
status table was generated showing the numbers and percentages of patients at each visit and 
the numbers and percentages of patients completing ≥1 item of the questionnaire at that cycle. 
Changes from baseline in total FACT-B and subscale scores occurring during treatment were 
assessed by subtracting baseline QOL score from follow-up visit scores. The primary 
prespecified PRO analysis to compare the 2 treatment groups was based on a longitudinal, 
mixed-effects, random-intercept, random-slope model.[9] The variables in the model are 
treatment, time, treatment by time, and baseline used as covariates. In fitting the mixed-effect 
model, time was used as a continuous variable and the method of restricted maximum 
likelihood was used and an unstructured covariance matrix was assumed. A linear function was 
used as the slope of line graph across timepoints was linear and the time trend did not differ by 
treatment assignment. Similar analyses were performed to compare the overall EQ-5D index 
and VAS scores between treatment arms. No adjustments for multiple comparisons were made.  
As part of the post-hoc analyses, an examination of the time to deterioration (TTD) in 
FACT-B total score was conducted using survival analysis methods including Kaplan-Meier plots, 
calculation of HRs and log-rank tests to compare the 2 treatment arms. TTD was defined as 
duration between baseline and first occurrence of a decrease of ≥7 points in FACT-B score with 
no subsequent observation of <7-point decrease. In addition, TTD in FACT-B scores was 
compared between the following groups in both treatment arms combined as well as in each 
treatment arm separately: patients with versus without objective response (complete response 
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or partial response according to Response Evaluation Criteria in Solid Tumors criteria [RECIST] v 
1.1.) and patients with a progression event versus those who did not progress. Although a one-
sided test at a significance level of 0.05 was used for consistency with the primary and key 
secondary time-to-event endpoints, the critical value used for interpretation for TTD was 
0.025.  
In addition, as part of post-hoc analyses, the change from baseline in the individual item 
assessing pain in body parts was carried out using repeated-measures mixed-effect analyses 
with baseline as a covariate. To assess the effect of neutropenia, patients with and without 
neutropenia were identified at each cycle and compared on change from baseline FACT-B and 
observed EQ-5D index scores using analysis of variance with baseline as a covariate. This 
analysis was performed only for the patients in the palbociclib plus letrozole arm as few 
patients in the placebo plus letrozole arm had neutropenia.  
All analyses were conducted using Statistical Analysis System software (SAS Institute, 
Cary, NC). All P values are 2-sided unless stated otherwise. 
RESULTS 
Patients and Disease Characteristics 
Baseline characteristics in the ITT population were well-balanced between the 2 treatment 
arms as previously reported.[4] Mean age was 62 years in the palbociclib plus letrozole arm and 
61 years in the placebo plus letrozole arm (Table S1). A total of 338 (76.1%) and 171 (77.0%) 
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patients had measurable disease at baseline in the palbociclib plus letrozole and placebo plus 
letrozole arms, respectively. Most patients in both treatment arms had Eastern Cooperative 
Oncology Group performance status of 0 or 1 (98%). More than one third of patients in each 
treatment arm had de novo disease and about 40% had 3 or more metastatic sites (Table S1).  
Completion Rates of PROs 
The percentage of patients completing at least 1 question from baseline to cycle 37 for FACT-B 
ranged from 95% to 100% in each treatment arm except for cycle 33 in the placebo plus 
letrozole arm, where an 80% completion rate was observed among 5 eligible patients (at the 
time of data cutoff with 22.3 months median follow-up). A summary of completion rates for 
FACT-B by treatment arm and cycle and the number of eligible patients available to complete 
the questionnaire is presented in Table S2; reasons for discontinuation overall and by 
treatment arm are presented in Table S3. 
FACT-B Total Scores 
Baseline mean (±standard deviation [SD]) scores for FACT-B total scores were similar for the 
palbociclib and the placebo plus letrozole arms (101.5 ± 19.1 vs 103.2 ± 18.7) comparable to 
healthy individuals (Table 1).[10] The overall change from baseline in FACT-B scores from the 
repeated-measures mixed model was not found to be significantly different (P=0.782) between 
the palbociclib plus letrozole arm (–0.11 [95% CI, –1.42 to 1.21]) and the placebo plus letrozole 
arm (0.22 [–1.68 to 2.12]); the treatment-by-time interaction term was not found to be 
significant (P=0.610). The change from baseline value did not reach the threshold of 7 points in 
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either treatment arm indicating that addition of palbociclib to letrozole did not have a clinically 
meaningful adverse impact on patient QOL. A Forest plot of between-treatment comparisons of 
change from baseline in total FACT-B and subscale scores is displayed in Figure 1. 
FACT-G Total and Subscale Scores 
Baseline mean (± SD) scores for FACT-G total scores were similar for the palbociclib plus 
letrozole arm and placebo plus letrozole arm (77.7 ± 15.5 vs 79.1 ± 15.4; Table 1). The overall 
change from baseline in FACT-G scores was not found to be significantly different (P =0.883) 
between the palbociclib plus letrozole (–0.39 [95% CI, –1.46 to 0.68]) and placebo plus letrozole 
(–0.53 [–2.08 to 1.02]) treatment arms (Figure 1). 
The overall change from baseline scores for PWB for the palbociclib plus letrozole arm 
versus the placebo plus letrozole arm were not found to be statistically significantly different 
between the 2 treatment arms (–0.50 [95% CI, –0.90 to –0.20] vs –0.30 [–0.80 to 0.30]), SWB (–
0.60 [–1.00 to –0.20 ] vs –0.70 [–1.20 to –0.10]), EWB (0.70 [0.40 to 1.00] vs 0.50 [0.10 to 0.90]) 
and FWB (0.20 [–0.20 to 0.60] vs 0.30 [–0.30 to 0.90]). Similarly no statistically significant 
difference was observed in overall change from baseline in the BCS (0.19 [95% CI, –0.18 to 0.56] 
vs 0.83 [0.29 to 1.37]) and FACT-B TOI (–0.10 [–1.00 to 0.81] vs 0.71 [–0.61 to 2.02]) scores 
between the palbociclib plus letrozole and the placebo plus letrozole arms (Figure 1). The 
treatment-by-time interaction term was not statistically significant in models for any scale 
(except for emotional functioning) indicating a similar time trend for PRO scores for both arms 
after adjusting for covariates. A significantly greater improvement from baseline was observed 
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in the scores of the item assessing pain in body parts (–0.256 [95% CI, –0.33 to –0.18] vs –0.098 
[–0.21 to 0.01]; P=0.018). 
Time to Deterioration Analyses 
An analysis of TTD in FACT-B showed a positive trend (HR<1) favoring the palbociclib plus 
letrozole arm but was not statistically significant (HR: 0.883 [95% CI, 0.673 to 1.158]; 1-sided P 
=0.1900). A Kaplan-Meier graph is provided in Figure 2A. 
Time to Deterioration Analyses Based on Progression Status and Objective Response 
The TTD analysis by progression status demonstrated a significantly greater TTD in HRQOL as 
assessed by the FACT-B total score in patients who had not progressed compared to those who 
did in the palbociclib plus letrozole arm (HR: 0.53; 1 –sided P<0.001; Figure S2A) and the 
placebo plus letrozole arm (HR: 0.57; 1 –sided P=0.009; Figure S2B) as well as in both treatment 
arms combined (HR: 0.53; 1- sided P<0.001; Figure S2C). 
The TTD analysis of patients with an objective response compared to those without, 
demonstrated a significantly greater TTD in HRQOL as assessed by the FACT-B total score in 
responders compared to non- responders. This was true based on individual treatment arms: in 
the palbociclib plus letrozole arm (HR: 0.410; 1-sided P<0.0001; Figure 2B) and in the placebo 
arm (HR: 0.553; 1-sided P=0.0064; Figure 2C) as well as based on all patients (HR: 0.452; 1-sided 
P˂0.0001; Figure 2D. 
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EQ-5D Health State Profile 
The percentage of patients reporting “extreme problems” for any descriptors was low in both 
treatment arms at baseline (Table 2) and did not change notably from baseline over the course 
of treatment.  
EQ-5D Index and VAS Scores 
Baseline EQ-5D index scores were similar between the palbociclib plus letrozole and the 
placebo plus letrozole arms (Table 2). Based on the longitudinal mixed-effect models, 
no statistically significant differences were observed in the overall EQ-5D index score on 
treatment between the palbociclib plus letrozole and placebo plus letrozole arms 
(0.74 [95% CI, 0.72 to 0.75] vs 0.71 [0.69 to 0.73]; P =0.093).  
Baseline EQ-5D VAS scores were also found to be similar between both study arms, and 
no statistically significant difference was observed between treatment arms during treatment 
(75.07 [95% CI, 73.87 to 76.27] vs 75.25 [73.51 to 76.99]) (Table 2).  
FACT-B and EQ-5D Index Scores Between Patients With and Without Neutropenia in the 
Palbociclib Plus Letrozole Arm 
No statistically significant differences were observed in the change from baseline in FACT-B 
total score at any cycle between patients with and without neutropenia in the palbociclib plus 
letrozole arm (Figure S3). No statistically significant differences were observed in the EQ-5D 
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index score at any cycle between patients with and without neutropenia except cycles 11, 13 
and 15 (P<0.05), in which the scores were higher in the patients with neutropenia (Figure S4).  
DISCUSSION 
Hormone receptor-positive MBC is not curable but can have a long natural history with multiple 
lines of sequential effective regimens. For this reason, it is critical when introducing new 
therapies with increased efficacy to demonstrate that QOL is not compromised. Although 
treatment can prolong time to disease progression, thereby forestalling the effects of disease, 
toxicity associated with treatment can adversely affect QOL. In general, patients receiving first-
line therapy for HR+/HER2– disease have high a functional level of QOL at the time of diagnosis, 
comparable to the general healthy population, and our current analysis provides confirmation 
of this finding. It is therefore even more important to understand the effect of treatment on 
patients’ overall QOL, and balance risk versus benefit. In the current study, we utilized 2 widely 
known and validated PRO questionnaires, one assessing breast cancer-specific HRQOL (FACT-B) 
and the other assessing general health status (EQ-5D). To our knowledge, the results presented 
here represent the longest period of follow-up to date in the published literature on PROs in 
women receiving endocrine-based therapy for HR+/HER2– MBC in the most contemporary care 
setting. This analysis shows that women on endocrine therapy are doing exceedingly well as 
evaluated by PROs, comparable to healthy individuals.[10] More importantly, results of 
outcomes assessed using FACT-B showed maintenance of QOL in both arms, without detriment 
from the addition of palbociclib.  
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Similar to the FACT-B total scores, the general health status scores assessed using the 
EQ-5D VAS suggest that the addition of palbociclib to letrozole does not have a significant 
adverse impact on a patient’s health status compared with letrozole alone. A significantly 
greater improvement in pain scores was observed in the palbociclib plus letrozole arm. These 
results are consistent with an earlier report for the palbociclib plus fulvestrant regimen as later-
line therapy.[11] 
Overall, maintenance of QOL in patients with MBC, at a level close to healthy individuals 
in the general population with a median duration of treatment of almost 2 years is a significant 
improvement over previous therapies, including targeted therapy over similar or shorter 
periods of time, and is clinically meaningful for patients.[12] 
In both arms, deterioration of FACT-Breast Total score was significantly delayed in 
patients without progression versus those with progression and patients with partial or 
complete response versus those without. It is worth noting that disease progression and tumor 
response in this study were assessed by RECIST, which is heavily reliant on radiographic imaging 
assessment. These data emphasize the value of radiological assessment on treatment effect 
and are supported by patients’ direct reported outcomes demonstrating the impact of 
differences in progression and response status (a physician-reported outcome) and QOL. The 
knowledge obtained from this analysis will add to the ongoing debate in the medical 
community regarding the implications of radiologically assessed versus clinically assessed 
disease progression for clinical practice and research. 
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Neutropenia is the main treatment-related adverse event associated with CDK4/6 based 
therapy, requiring complete blood count monitoring in the palbociclib plus letrozole arm; 
however, neutropenia has been shown to have a neutral and/or no negative impact, if any, on 
patients’ QOL (Figure S3 and 4). 
Potential limitations in the design of PRO analyses should be considered when 
interpreting these results. The assumption that missing data were missing at random in the PRO 
analysis may be incorrect, and bias could occur as a result. To address this limitation, the mixed-
model approach was chosen because it is robust as long as the proportion of missing data that 
cannot be ignored is reasonably small (<5%) as was the case in this study.  
Despite these limitations, the patient-reported QOL in this study provides clear evidence 
about a critical component of the risk-benefit profile from first-line palbociclib plus letrozole. 
These data demonstrate that overall QOL in patients receiving first-line endocrine-based 
therapy is maintained at high level, and that patients’ QOL is not negatively affected by the 
addition of palbociclib to letrozole. Maintenance of QOL close to general healthy population 
norms for more than 2 years is clinically meaningful. In conclusion, the addition of palbociclib to 
letrozole significantly improves PFS while maintaining HRQOL and general health status in 
treatment-naïve, postmenopausal women with ER+/HER2− MBC. This observation is 
maintained regardless of the occurrence of neutropenia while deterioration of QOL is delayed 
in patients with response and/or no progression.  
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Figure 1. Between treatment comparison of overall change from baseline in FACT-B scores. 
FACT-B, Functional Assessment of Cancer Therapy–Breast; FACT-G, Functional Assessment of 
Cancer Therapy–General; TOI, Trial Outcome Index.  
Figure 2. Time to deterioration in Functional Assessment of Cancer Therapy–Breast (FACT-B) 
score.  
Online-only Supplemental Materials 
 
 
Figure S1. Patient Disposition  
a
The patient-reported outcome (PRO)-evaluable population includes patients in the intent-to-
treat population with a baseline and ≥1post-baseline assessment before the end of the study 
treatment. Patients must have completed all 5 items needed to calculate the index-based 
summary score at the respective cycle. 
b
The patient-reported outcome (PRO)-evaluable 
population includes patients in the intent-to-treat population with a baseline and ≥1 post-
baseline assessment before the end of the study treatment. Patients must have completed all 5 
items needed to calculate the index-based summary score at the respective cycle. 
c
Patients 
who discontinued palbociclib or placebo could continue to receive letrozole alone. EQ-5D, 
EuroQoL 5 dimensions; FACT-B, Functional Assessment of Cancer Therapy-Breast. 
 
Figure S2. Time to Deterioration in FACT-B Total Scores in Patients With Versus Without a 
Progression Event in the (A) palbociclib plus letrozole arm, (B) placebo plus letrozole arm, (C) 
both treatment arms combined. CI, confidence interval; FACT-B, Functional Assessment of 
Cancer Therapy-Breast; Mo, months; NE, not evaluable; PFS, progression free survival. 
 
Figure S3. Change from Baseline in FACT-B Scores in Patients With and Without Neutropenia. 
FACT-B, Functional Assessment of Cancer Therapy-Breast. 
 
Figure S4. EQ-5D Index Scores in Patients With and Without Neutropenia in the Palbociclib Plus 
Letrozole Arm. EQ-5D, EuroQoL 5 dimensions.  
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Table 1. Baseline FACT-B Scores  
Domain 
Palbociclib + Letrozole 
Mean (SD) 
Placebo + Letrozole 
Mean (SD) 
Normative 
Scores[10]
 
Mean (SD) 
Physical well-being  21.9 (5.5) 21.8 (5.4) 22.1 (5.4) 
Social/family well-being  21.8 (5.9) 22.2 (5.6) 19.8 (6.8) 
Emotional well-being  16.3 (4.7) 16.6 (4.7) 19.4 (5.1) 
Functional well-being  17.5 (6.0) 18.3 (6.0) 18.3 (6.9) 
Breast cancer subscale  24 (5.6) 24.2 (5.5) NA 
Trial Outcome Index  63.4 (13.6) 64.3 (13.3) NA 
FACT-G total 77.7 (15.5) 79.1 (15.4) 79.6 (18.6) 
FACT-B total 101.5 (19.1) 103.2 (18.7) NA 
Pain 1.8 (1.3) 1.8 (1.3) NA 
Abbreviations: FACT-B, Functional Assessment of Cancer Therapy–Breast; FACT-G, Functional 
Assessment of Cancer Therapy–General; NA, not available; SD, standard deviation. 
For FACT-B total, FACT-G total, and each of the subscales, a higher score indicates better well-
being or quality of life. For the pain item, higher scores indicate greater pain severity. 
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Table 2. EQ-5D Scores at Baseline and Overall on Treatment Scores 
 Palbociclib + Letrozole 
(n=437) 
Placebo + Letrozole  
(n=218) 
Heath State (at Baseline) n 
No 
Problem 
n (%) 
Some 
Problem 
n (%) 
Extreme 
Problem 
 n (%) N 
No 
Problem 
n (%) 
Some 
Problem 
n (%) 
Extreme 
Problem 
 n (%) 
Mobility 436 
268 (61.5) 
166 
(38.1) 
2 (0.5) 
215 
132(61.4) 83 (38.6) 0 
Self care 436 383 (87.8) 50 (11.5) 3 (0.7) 215 189 
(87.9) 
25 (11.6) 1 (0.5) 
Usual activities 436 244 (56.0) 173 
(39.7) 
19 (4.4) 215 131 
(60.9) 
78 (36.3) 6 (2.8) 
Pain/discomfort 436 135 (31.0) 277 
(63.5) 
24 (5.5) 215 76 (35.3) 132 (61.4) 7 (3.3) 
Anxiety/depression 436 202 (46.3) 212 
(48.6) 
22 (5.0)  215 99 (46.0) 111 (51.6) 5 (2.3) 
 
EQ-5D index scorea  Mean SD  95% CI  Mean SD  95% CI 
Baseline  436 0.697 0.25 0.67−0.72 215 0.730 0.21 0.70−0.76 
Overall on treatmentb NA 0.736 NA 0.72−0.75 NA 0.712  NA 0.69−0.73 
End of treatment 181 0.630 0.30 0.59−0.67 129 0.662 0.30 0.61−0.71 
EQ-5D VASa         
Baseline  432 71.3 21.16 69.3−73.3 216 72.3 19.83 69.7−75.0 
Overall on treatmentb  NA 75.07 NA 73.87−76.2
7 
NA 75.25 NA 73.51−76.99 
End of treatment  181 68.0 21.81 64.8−71.2 131 70.1 21.11 66.5−73.8 
Abbreviations: CI, confidence interval; EQ-5D, EuroQoL 5 dimensions questionnaire; SD, standard deviation; VAS, visual analog 
scale.  
aHigher EQ-5D index and VAS scores indicate better health status/quality of life. 
Downloaded from https://academic.oup.com/annonc/advance-article-abstract/doi/10.1093/annonc/mdy012/4817337
by guest
on 06 February 2018
bEstimated from a repeated-measures mixed effects model with baseline, treatment, time, and treatment × time interaction terms as 
covariates.  
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Figure 1. Between treatment comparison of overall change from baseline in FACT-B scores. FACT-B, 
Functional Assessment of Cancer Therapy–Breast; FACT-G, Functional Assessment of Cancer Therapy–
General; TOI, Trial Outcome Index.  
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Figure 2. Time to deterioration in Functional Assessment of Cancer Therapy–Breast (FACT-B) score.  
Between treatment comparison of time to deterioration in FACT-B score among all patients (A), Comparison 
of time to deterioration in FACT-B score between responders and non-responders (based on objective 
response status) in (B) the palbociclib plus letrozole arm, (C) the placebo plus letrozole arm, and (D) both 
treatment arms combined. CI, confidence interval; Mo, months; NE, not estimable; NR, not reached.  
 
215x279mm (300 x 300 DPI)  
 
 
Downloaded from https://academic.oup.com/annonc/advance-article-abstract/doi/10.1093/annonc/mdy012/4817337
by guest
on 06 February 2018
